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a  b  s  t  r  a  c  t
Pneumoviruses  such  as  pneumonia  virus  of  mice  (PVM),  bovine  respiratory  syncytial  virus  (bRSV)  or
human  (h)RSV  are  closely  related  pneumoviruses  that cause  severe  respiratory  disease  in  their  respective
hosts.  It  is  well-known  that  T-cell  responses  are  essential  in  pneumovirus  clearance,  but pneumovirus-
speciﬁc  T-cell  responses  also  are  important  mediators  of  severe  immunopathology.  In  this  study  we
determined  whether  memory-  or  pre-existing,  transferred  virus-speciﬁc  CD8+ T-cells  provide  protection
against  PVM-induced  disease.  We  show  that  during  infection  with  a sublethal  dose  of  PVM,  both  natural
killer  (NK)  cells  and  CD8+ T-cells  expand  relatively  late.  Induction  of  CD8+ T-cell  memory  against  a single
CD8+ T-cell  epitope,  by  dendritic  cell (DC)-peptide  immunization,  leads  to  partial  protection  againstK  cell
D8+ T-cell
accine
PVM  challenge  and  prevents  Th2  differentiation  of  PVM-induced  CD4  T-cells.  In  addition,  adoptively
transferred  PVM-speciﬁc  CD8+ T-cells,  covering  the  entire  PVM-speciﬁc  CD8+ T-cell  repertoire,  provide
partial  protection  from  PVM-induced  disease.  From  these  data  we  infer  that antigen-speciﬁc  memory
CD8+ T-cells  offer  signiﬁcant  protection  to PVM-induced  disease.  Thus,  CD8+ T-cells,  despite  being  a
major  cause  of  PVM-associated  pathology  during  primary  infection,  may  offer promising  targets  of  a
accinprotective  pneumovirus  v
. Introduction
Pneumoviruses are an important cause of respiratory infections
n mammals [1]. One well-known member of the pneumovirus
enus is hRSV, a major cause of severe respiratory disease in
nfants and elderly [2]. A failed vaccine trial using formalin-
nactivated hRSV (FI-RSV) in the 1960s that led to enhanced disease
nstead of immune protection [3–6], has triggered intense efforts to
Abbreviations: BAL, bronchoalveolar lavage; BALF, BAL ﬂuid; DC, dendritic cell;
M-DC, bone marrow derived DC; DCp, peptide-loaded DC; FI, formalin inacti-
ated;  hRSV, human respiratory syncytial virus; ID, infectious dose; EID, egg ID; i.n.,
ntranasal; i.p., intraperitoneal; i.v., intravenous; MLN, mediastinal lymph node; NK,
atural killer; NS, nonstructural; p.i., post infection; pfu, plaque forming units; PVM,
neunomia virus of mice; SEM, standard error of mean.
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edicine,  University of Utrecht, Yalelaan 1, 3584 CL Utrecht, The Netherlands.
el.: +31 302532471; fax: +31 302533555.
E-mail addresses: d.zaiss@uu.nl (D.M.W. Zaiss), e.j.a.m.sijts@uu.nl (A.J.A.M. Sijts).
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© 2012 Elsevier Ltd. 
elucidate how to induce immune responses that can prevent or
protect against natural hRSV infection without causing pathology.
Different studies in humans and mouse models have shown that
antibodies can contribute to immune protection [7–10]. However,
the antibodies induced during natural hRSV infection fail to pre-
vent recurrent infections throughout life, indicating that also the
efﬁcacy of vaccine-induced neutralizing antibodies may  be limited
[7,11]. Controversy also exists concerning the precise role of the T
cell compartment in pneumovirus-induced disease [12,13]. Several
studies have shown that although T cells are essential in eradicat-
ing established infections [14], they also are important mediators
of hRSV-induced immunopathology [15–19]. In murine models,
especially Th2 skewing of the CD4+ T-cell lineage after immuniza-
tion with FI-RSV or hRSV-G protein encoding recombinant Vaccinia
virus vectors have been shown to lead to enhanced disease follow-
Open access under CC BY license.ing subsequent hRSV infection [12,13,20]. Induction of CD8+ T-cell
responses, on the other hand, inhibited vaccine-enhanced pul-
monary disease [21–23]. Thus, despite the notion that T cells play
a role in pneumovirus-induced immunopathology, these studies
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uggest that vaccines designed to induce antipneumoviral CD8+ T
ell responses may  offer an alternative to vaccines targeting the
umoral response.
Pneumoviruses display a narrow host range and several species-
peciﬁc variants have been described [1], adapted for evasion
f defense mechanisms in their speciﬁc hosts [24,25]. Therefore,
nstead of hRSV, its mouse-adapted variant PVM is increas-
ngly used to study pneumovirus-speciﬁc immune responses and
mmunopathogenesis in mouse models. PVM and hRSV display
 marked genetic similarity and use similar evasion strategies
26–28]. Intranasal (i.n.) administration of a low PVM inoculum
esults in effective replication and severe respiratory disease in
ice, with several hallmarks similar to severe hRSV disease in
umans, including severe pulmonary inﬂammation, edema, and
nﬂux of granulocytes [29].
Although extensively studied during hRSV infections in mouse
odels, only limited studies evaluated T cells in PVM infected mice
30,31]. Frey et al. showed that, like in hRSV-infection, T-cells are
ssential for viral elimination in PVM-infected mice, but are also
mportant mediators of infection-associated pathology [31]. This
bservation raises the question of whether a pneumovirus-vaccine
hat targets CD8+ T cell responses would be safe. In this study,
e used the PVM mouse model of respiratory infection to deter-
ine whether pre-existing virus-speciﬁc CD8+ T-cells may  provide
rotection against pneumovirus-induced disease.
. Material and methods
.1.  Virus stocks, mice and infection
PVM strain J3666 was  passaged in mice to retain full pathogenic-
ty and hRSV strain A2 was grown in BSC-1 cells and concentrated as
escribed [32]. For both viruses, plaque assays on BSC-1 cells were
erformed to determine viral titers. Inﬂuenza strains A/HK/x31
H3N2) and A/PR/8/34 (H1N1) were grown as described [33]. Age-
atched 7–10 week old female BALB/c mice were purchased from
harles River, anesthetized with isoﬂurane and then infected i.n.
ith 5 × 106 pfu RSV in 50 l, or with 1 × 105 EID50 HKx31 or 150
ID50 PR8 in 30 l PBS as described [33], or with the indicated doses
f PVM in 30 l PBS. All animal experiments were approved by the
ommittee on Animal Experiments of the University of Utrecht.
.2.  Sample preparation
Mice  were sacriﬁced by injection of sodium pentobarbital and
ronchoalveolar lavage (BAL) was collected by three times lavage
ith 1 ml  PBS containing 10 M EDTA. Thereafter, lungs were
erfused with PBS, excised, minced and incubated in PBS con-
aining collagenase (2.4 mg/ml; Roche Applied Science) and DNase
1 mg/ml; Roche Applied Science) for 30 min  at 37 ◦C, passed
hrough a cell strainer and lymphocytes were puriﬁed using
ympholyte-M (Cederlane). For mRNA isolation, the right lung was
laced in 1 ml  TRIzol (Invitrogen).
.3. Flow cytometry
Fluorochrome-conjugated antibodies were purchased from
Bioscience [CD69 (H1.2F3), CD49b (DX5), TCR (H57-597), NKp46
29A1.4), CD62L (MEL-14), IFNy (XMG1.2), CD8 (53-6.7), CD11c
N418), CD19 (MB19-1), CD4 (RM4-5), MHC-II (m5/114.15.2)]
r BD Pharmingen [Siglec-F (E50-2440)]. PE-labeled MHC  class
 tetramers were prepared in collaboration with D. Busch (TU-
uenchen), by refolding H2-Kd heavy chains and human 2m
n the presence of synthetic inﬂuenza-derived NP147–155 (TYQR-
RALV), hRSV M282–90 (SYIGSINNI) or PVM P261–269 (CYLTDRARI).
ell  surface markers were stained as described [34]. For tetramere 30 (2012) 6382– 6388 6383
stainings,  cells were incubated with 1 g tetramer for 1 h at 4 ◦C
and then stained for surface markers. To measure IFN production,
BAL cells were stimulated 1:1 with YAC cells for 4 h (NK cell acti-
vation) or with 2 M P261–269 for 6 h (CD8+ T-cell stimulation) in
100 l RPMI medium containing 10% FCS, glutamax, antibiotics and
30 M -mercaptoethanol, and 10 M monensin and then stained
as described [34]. Cells were analyzed on a FACS Calibur or Canto II
(BD Biosciences) using FlowJo software (Tree Star).
2.4. Preparation of peptide-loaded bone marrow (BM)-DC and
FI-PVM
Mouse  BM-DC were expanded for 6 days in RPMI medium
with 15% GM-CSF (culture supernatant of X63Ag cells), activated
overnight with 100 ng/ml LPS and then pulsed for 1 h with 2 M
P261–269. Mice were immunized intravenously (i.v.) with 5 × 106
peptide-loaded BM-DC in 200 l PBS. FI-PVM was prepared as
described [6] and was  administered in 100 l s.c. Mice were
infected with PVM, 3–5 weeks after immunization.
2.5. Quantitative real-time PCR
Total lung RNA was  puriﬁed using TRIzol (Invitrogen) and cDNA
was transcribed (iScript cDNA Synthesis Kit; Bio-Rad Laboratories).
PVMSH RT-PCR was performed as described [35] in an iCycler (Bio-
Rad Laboratories), 95 ◦C for 10 min  and then 45 cycles of 95 ◦C for
15 s and 60 ◦C for 60 s. Copy numbers per lung were calculated from
a standard curve generated using serially diluted PVM-SH cDNA.
RT-PCR for IL-4, IFN and GAPDH were performed using the Taq-
Man Gene Expression Assays (Applied Biosystems) Mm00445259,
Mm00801778 and Mm99999915. Relative expression of IL-4 and
IFN normalized against GAPDH were calculated using a ﬁxed point
of the standard curve as calibrator.
2.6. Multiplex bead-based assay
To quantify IL-4 and IFN, ﬂuoresceinated microbeads coated
with capture antibodies (IL-4: BVD-1D11; IFN-:AN-18) were
added to 50 l BAL ﬂuid and incubated overnight at 4 ◦C. Cytokines
were detected with biotinylated anti-IFN (XMG1.2) and -IL-4
(BVD6-24G2), and PE-labeled streptavidin. Fluorescence was mea-
sured using a Luminex model 100 XYP (Luminex, Austin, TX, USA).
Antibodies were purchased from BD Biosciences.
2.7. Adoptive transfer of CD8+ T-cells
Naïve and PVM-infected (d. 14 p.i.) donor mice were sacriﬁced,
single cell suspensions prepared of lungs, spleens and MLNs were
mixed and stained with PE-labeled antibodies against CD19, CD4,
MHC-II and NKp46 (without Fc-block). Negative selection was  per-
formed using a BD Inﬂux (BD Biosciences). Recipient mice received
5 × 106 enriched cells in 200 l PBS i.v., and then were infected with
PVM.
3. Results
3.1. Dynamics of CD8+ T-cell responses in PVM-infected mice
Intranasal  infection with 25 pfu of PVM strain J3666 induced
severe but sublethal disease in BALB/c mice, with weight reduction
of approximately 15–20% of original body weight (data not shown).
During the ﬁrst days of infection, PVM rapidly replicated to high
numbers (Fig. 1A). Viral copy numbers peaked at d. 8 p.i. and then
declined.
In order to determine their protective capacity, we ﬁrst studied
CD8+ T-cell kinetics during primary PVM infection and compared
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Fig. 1. CD8+ T-cell kinetics in PVM and inﬂuenza-infected mice. BALB/c mice were infected i.n. with approximately 25 pfu PVM or 1 ×105 EID50 inﬂuenza A/HK-x31 and
sacriﬁced at the indicated days p.i. (A) PVM virus titers in the right lung determined by quantitative RT-PCR and converted to PVM-SH gene copy numbers per lung. The
dotted line indicates the detection limit. Results are shown as mean ± SEM with 3 mice per group. (B) Frequency of total CD8+ T-cells as percentage of lymphocytes in the
BAL  determined by ﬂow cytometry at the indicated days p.i. Results are shown as mean ± SEM with 3 mice per group. (C) Frequencies of virus-speciﬁc CD8+ T-cells in the
BAL  were determined by staining with MHC  class I tetramers loaded with NP147–155 (inﬂuenza tetramer) or M282–290 (hRSV tetramer), and tetramers loaded with unrelated
peptides were used to measure background staining. The percentage of virus-speciﬁc CD8+ T-cells in the BAL of inﬂuenza (left graph) or hRSV (right graph) infected mice
(CD62L−tetramer+) are shown after subtraction of background staining. (D and E) Frequencies of virus-speciﬁc CD8+ T-cells in the BAL of PVM infected mice, determined as
described in (C) with P261–269-peptide loaded MHC  class I tetramers. (D) Graph showing the results of individual mice and (E) representative FACS plots (gated on CD8+ cells)
show the percentage of PVM tetramer+ (tet+) or hRSV tetramer+ CD62L− cells at the indicated days p.i. (F, G) BAL cells from PVM-infected mice were restimulated ex vivo for
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xperiments. BAL of uninfected mice did not contain any cells or detectable viral lo
hese with the well-described CD8+ T-cell responses in inﬂuenza
nd hRSV-infected mice [36,37]. The relative proportions of CD8+
-cells in the airways of PVM-infected mice strongly increased
ver time (Fig. 1B), and from d. 10 onwards approximately 60%
f lymphocytes in the BAL were CD8+ T-cells. In inﬂuenza- and
RSV-infected mice, initially, the proportions of CD8+ T-cells in the
irways were higher than in PVM-infected mice but then dropped,
hen relative proportions of CD8+ T-cells in PVM-infected mice
ere still rising (Fig. 1B). Quantiﬁcation of virus-speciﬁc CD8+ T-
ells with MHC  class I tetramers containing a dominant epitope
f either PVM (P261–269 [30]), inﬂuenza (NP147–155 [38]) or hRSV
M282–90 [39]), demonstrated that NP147–155- and M282–90-speciﬁc
D8+ T-cells were detectable at d. 6 p.i. and expanded until d.
–10 p.i. when a plateau was reached (Fig. 1C). In PVM-infected
ice, the BAL did not contain any P261–269-speciﬁc CD8+ T-cells
t d. 6 p.i, and only a small population of P261–269-speciﬁc CD8+
-cells could be detected at d. 8 p.i. (Fig. 1D and E). The relative
roportions of P261–269 tetramer+ CD8+ T-cells further increased
ntil d. 10 p.i. after which levels remained high (Fig. 1D and E).
o determine whether PVM-speciﬁc CD8+ T-cell were functional,
e quantiﬁed IFN production in virus-speciﬁc CD8+ T-cells after
x vivo P261–269 stimulation. Consistent with earlier publications
30,37], we found that IFN producing P261–269-speciﬁc CD8+ T-
ells were barely detectable at d. 8 of infection (Fig. 1F and G)
ut then increased in numbers. At any time point of infection,
he relative proportions of IFN-producing P261–269-speciﬁc CD8+s showing the results of individual mice (background frequencies in the absence of
CD8+ cells after peptide restimulation. Data are representative of two independent
T-cells remained lower than that of P261–269 tetramer-stained
cells.  From these data we  conclude that high proportions of CD8+
T-cells migrate to the lungs of PVM infected mice and that the
appearance of virus-speciﬁc CD8+ T-cells in the airways is slightly
delayed compared to inﬂuenza virus- or hRSV-infected mice.
3.2.  Dynamics of innate responses to PVM infection
As PVM-speciﬁc CD8+ T-cells migrated relatively late to the
lungs of PVM infected mice, we  wondered whether migration of
other immune cells was delayed also. Quantiﬁcation of NK cells in
the BAL demonstrated a prominent inﬂux of NK cells into the air-
ways of PVM-infected mice at d. 6 of infection, when approximately
50% of total inﬁltrating lymphocytes were NK cells (Fig. 2A, left
panel). In absolute numbers (Fig. 1A, right panel) NK cell responses
in PVM-infected mice peaked between days 8 and 10 of infection
and then declined. In comparison, in the airways of inﬂuenza strain
HKx31-infected mice (Fig. 1A) a large inﬂux of NK cells, represent-
ing approximately 60% of total lymphocytes, was detected already
at d. 2 p.i. with absolute numbers of inﬁltrating NK cells peaking
at d. 3 of infection. Similar results were obtained in analyses of the
BAL of hRSV-infected mice (Supplemenary Fig. 1). Both in inﬂuenza-
and in PVM-infected mice, BAL NK cells displayed an activated phe-
notype (high CD69) and produced IFN upon stimulation ex vivo
(Fig. 2B and C), indicating that they were functional. Thus, PVM-
infected mice show a marked inﬂux of NK cells into the airways,
M.J.G. van Helden et al. / Vaccin
Fig. 2. NK cell responses in PVM-infected mice compared to inﬂuenza-infected
mice.  BALB/c mice were infected i.n. with approximately 25 pfu PVM or 1 × 105 EID50
inﬂuenza A/HK-x31 and sacriﬁced at the indicated days p.i. (A) NK cells (TCR−DX5+)
as percentage of total lymphocytes (left panel) or in absolute numbers (right panel)
in the BAL, as determined by ﬂow cytometry. (B) Mean ﬂuorescence intensities (MFI)
of CD69 expression on NK cells in the BAL. (C) Percentage of IFN producing NK
cells  in the BAL after ex vivo restimulation with YAC cells (1:1) in the presence
of  monensin for 4 h. (D) Mice were infected with 150 EID50 inﬂuenza PR8, 25 pfu
P
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nVM  (normal dose) or 1250 pfu PVM (high dose) and absolute numbers of NK cells
DX5+NKp46+TCR−) in the BAL were determined. Results are shown as mean ± SEM
or 3 mice per group. n.d., not determined.
lthough at a later time point than in mice infected with inﬂuenza
r hRSV.
PVM is a natural mouse pathogen and, unlike in case of HKx31,
nly a few viral particles sufﬁce to establish severe disease in mice.
o determine whether the low numbers of infecting virus particles
xplains for the shifted kinetics of NK cell responses in PVM com-
ared to HKx31-infected mice, NK cell inﬂux into the airways of
VM-infected mice was compared to that in mice infected with the
ouse-adapted inﬂuenza strain PR8, which is more virulent than
Kx31 and therefore used at 100–1000 fold lower concentration.
till, like HKx31, infection with PR8 (150 EID50) induced a promi-
ent early NK cell inﬂux into the airways (Fig. 2D, d. 2 and 4 p.i).e 30 (2012) 6382– 6388 6385
Conversely,  mice infected with a high dose of PVM (1250 pfu) lacked
NK cells in the BAL at d. 2 p.i., and only minor numbers of NK cells
were detected at d. 4 p.i. (Fig. 2D). In conclusion, both CD8+ T-cells
and NK cells migrate to the BAL at a much later time point fol-
lowing infection with PVM than with inﬂuenza. The relatively late
inﬂux of NK cells into the airways of PVM-infected mice is likely
to be explained by speciﬁc properties of this pneumovirus rather
than by the low numbers of viral particles administered to cause
infection.
3.3. P261–269-speciﬁc memory CD8+ T-cells provide partial
protection against PVM-induced disease
It has been shown that in PVM-infected mice, T-cells are respon-
sible for viral clearance, but are also involved in immunopathology
[31]. To determine whether PVM-speciﬁc memory CD8+ T-cells
may confer immune protection, mice were immunized with GM-
CSF-expanded BM-DC loaded with synthetic P261–269 (DCp) and
then challenged with PVM. As shown in Fig. 3A and B, numbers
of P261–269-speciﬁc CD8+ T-cells detected in the BAL of immunized
mice were substantially higher than in non-immunized controls
(Fig. 3A and B). Over the duration of the infection, DCp-primed mice
lost less weight (Fig. 3C), displayed signiﬁcantly reduced total-cell
inﬂux in the BAL (Fig. 3D), viral loads were signiﬁcantly lower than
in non-immunized mice (Fig. 3E), and peribronchial and interstitial
cellular inﬁltrates were reduced (Supplementary Fig. 2), indicating
an enhanced control of disease and viral loads.
Since vaccination with FI-PVM elicits an enhanced Th2 response
upon PVM infection [40], we  investigated the effect of DCp immu-
nization on CD4 T-cell differentiation during PVM challenge.
Compared with FI-PVM-immunized controls, mice immunized
with P261–269-loaded DC displayed elevated amounts of IFN mRNA
and cytokine levels in the lungs following challenge, indicating that
they had developed a Th1-skewed immune response (Fig. 4A and
B; upper panels). In contrast, FI-PVM immunized mice developed a
Th2-skewed response, as indicated by the relatively high levels of
IL-4 in the lungs (Fig. 4A and B; lower panels) and eosinophilia in
two  out of four mice (Fig. 4C and D). Thus, the presence of memory
CD8+ T-cells speciﬁc for a single PVM-epitope led to enhanced con-
trol of virus replication and prevented Th2 skewing of PVM-induced
CD4 T-cell responses upon PVM challenge, leading to a reduction
of PVM-induced disease.
3.4.  Protection conferred by adoptively transferred PVM-speciﬁc
CD8+ T-cells
Since  immunization with P261–269-loaded DC provided partial
protection, we decided to assess the protective capacity of the total
PVM-speciﬁc CD8+ T-cell response, targeting multiple epitopes. A
mix  of CD8+ T-cells enriched from the spleen, MLN  and lungs of
PVM-infected or uninfected mice were adoptively transferred into
recipient mice that then were infected with PVM. At d. 7 p.i. a clear
population of P261–269-tetramer+ cells was  detectable in the lungs
of mice that had received CD8+ T-cells of PVM-infected donors, but
not in the lungs of recipients that had received naïve CD8+ T-cells
of uninfected controls (Fig. 5A and B). In addition, recipients receiv-
ing immune cells from infected mice showed signiﬁcantly reduced
weight-loss and viral load (Fig. 5C and D). These results show that
PVM-speciﬁc CD8+ T-cells, despite being a major cause of pathol-
ogy in pneumovirus infections, can provide protection against PVM
infection.4. Discussion
Despite the fact that hRSV is a major cause of disease in infants,
there still are major gaps in our knowledge of the host response
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Fig. 3. Effects of DCp immunization on control of PVM infection. Mice were immunized i.v. with 5 × 106 P261–269-loaded BM-DCs or left untreated, and infected i.n. with
approximately 15 pfu PVM 3–5 weeks later. 4–5 mice per group were sacriﬁced on d. 8 and 14 after PVM infection. (A and B) Frequency of P261–269-speciﬁc CD8+ cells in
the BAL at d. 14 p.i. determined by tetramer staining as described in the legend to Fig. 2. (A) Representative FACS plots (gated on CD8+ cells), and (B) corresponding graphs
showing results for individual mice. (C) Body weight of individual mice as a percentage of
the  right lung determined by quantitative RT-PCR and converted to PVM-SH gene copy num
was  performed using a Mann–Whitney U-test. *p < 0.05.
Fig. 4. Cytokine production and eosinophils in the airways of PVM-infected, DCp-
compared to FI-PVM-immunized mice. 4–5 mice per group were immunized i.v.
with 5 × 106 P261–269-loaded BM-DCs, or s.c. with FI-PVM, and infected i.n. with
approximately 15 pfu PVM 3–5 weeks later. (A) Relative expression of IFN (upper
graph)  or IL-4 (lower graph) mRNA in the lungs 5 days after PVM infection, deter-
mined  by Q RT-PCR. (B) Levels of IFN (upper graph) and IL-4 (lower graph) in the
BAL ﬂuid on d. 5 p.i., determined by luminex. (C) FACS plots showing an example
of CD11c and Siglec-F staining on BAL cells of immunized mice 14 days after PVM
infection. Gated samples were eosinophils (CD11c−Siglec-F+) as described [42]. (D)
Frequency of eosinophils in the BAL of individual immunized mice 14 days after
PVM infection, determined by ﬂow cytometry. Statistical analysis was  performed
using  a Mann–Whitney U-test. *p < 0.05. their initial weight. (D) Total numbers of cells in the BAL at d. 8 p.i. (E) Virus titer in
bers. Data are representative of two independent experiments. Statistical analysis
against this virus. There is an increasing interest in using the natu-
ral mouse pathogen PVM to mimic  and study severe pneumovirus
infections. We  have used this model to study the role of CD8+ T-
cells in conferring protection against disease. Inﬂux of both NK
and CD8+ T-cells into the BAL of PVM-infected mice was markedly
delayed compared to that in mice infected with inﬂuenza or hRSV
(Figs. 1 and 2). However, from d. 10 p.i. onwards, extremely high
numbers of CD8+ T-cells were present in the airways of PVM-
infected mice, coinciding with disease. The relatively late immune
activation seen in the PVM-infected mice was not explained by
the quantities of administered viral particles, as both sublethal
and lethal doses of PVM failed to induce an early NK cell inﬂux
in the infected respiratory tissue (Fig. 1), whereas both high dose
HKx31 and low dose PR8 (representing comparable ID50s) caused
an early NK cell inﬂux, well detectable at d. 2 p.i. If not the quan-
tities of administered particles, differing replication kinetics may
explain the differences in kinetics of immune activation between
PVM and inﬂuenza infection, although it should be noted that PVM
rapidly replicates during the ﬁrst days of infection, reaching titers
of approximately 105 particles/lung at d. 2 p.i. (Fig. 1). Alternatively,
the relatively late inﬂux of lymphocytes into the airways of PVM-
infected mice is consistent also with recent observations that the
nonstructural proteins of PVM (NS1 and NS2) inhibit type I and type
III interferon responses [27,28]. In these studies, inﬂammation in
the airways of PVM-infected mice was found to be still limited at
d. 3 p.i., while at d. 6 p.i., high levels of chemokines and cytokines
such as MCP-1, RANTES, MIP-1 and IL-15 were produced [27,28].
These chemokines are likely to attract NK cells to the airways, as
well as CD8+ T-cells [31].
The ﬁnding that CD8+ T-cells cause pathology in the PVM-
mouse model [31] has raised questions about the use of a vaccine
designed to stimulate a pneumovirus-speciﬁc CD8+ T-cell response.
However, we  show that mice immunized with BM-DCs pulsed
with PVM P261–269 displayed a Th1-skewed immune response and
reduced viral loads following challenge (Figs. 3 and 4), suggest-
ing that vaccine-induced CD8+ T-cell memory protects against
pneumovirus-induced disease. In an earlier study [41], immuniza-
tion with PVM P261–269 in IFA was unsuccessful in protecting mice
against PVM-infection unless co-administered with a PVM-derived
CD4 T-cell epitope. Interestingly, the peptide/IFA immunization
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Fig. 5. Effects of CD8+ T-cell transfer on PVM infection. CD8+ T-cells enriched from pooled lung-, spleen- and MLN-cells of PVM-infected (d. 14 p.i.) or naïve donor mice
were transferred i.v. into recipient mice that were subsequently infected with approximately 25 pfu PVM and sacriﬁced at d. 7 p.i. (A) Representative FACS plots of gated
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rotocol used in that study resulted in mixed Th1/Th2 responses
o the included CD4 T-cell epitope, in contrast to the Th1 responses
bserved in PVM-challenged DCp-immunized mice (Fig. 3). Thus,
mmunization-induced PVM-speciﬁc memory CD8+ T-cells protect
gainst PVM-associated disease, but the degree of protection and
ffects of immunization on CD4 T-cell differentiation depend on
he strategy for epitope delivery and used adjuvant. Importantly,
ransfer of CD8+ T-cells isolated from PVM-infected mice, which
re targeted to a broad range of epitopes, almost entirely abro-
ated weight-loss in recipients and signiﬁcantly reduced viral loads
ollowing challenge with PVM (Fig. 5). Taken together, the data
resented here demonstrate that the presence of already primed
VM-speciﬁc CD8+ T-cells at the time point of PVM-infection
eads to enhanced control of viral loads and prevents T-cell-driven
mmunopathology.
In conclusion, we have shown PVM-speciﬁc CD8+ T-cells pro-
ide partial protection against PVM-induced disease, probably by
reventing Th2 skewing of PVM-speciﬁc immune responses and
y early control of viral loads. Our ﬁndings strongly suggest that
neumovirus vaccines designed to induce antigen-speciﬁc CD8+
-cell memory may  offer effective protection against pneumovirus-
nduced disease.
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